Carcinotech offers assay-ready cancer models for drug discovery, screening, and pre-clinical testing. These innovative models are validated to ensure consistency, use advanced AI-driven manufacturing to ensure high-throughput and robust results, and are quality controlled to produce highly predictive assay-ready models. Our in vitro models are very close to clinical biopsy samples as we get patient-specific cells and isolated cells from biopsies, which allow us to develop models representing cancer heterogeneity. These models can be manufactured to order and delivered assay-ready to your labs. Our team of 3D oncology experts also offer assay services for each drug compound utilising these advanced models, allowing for flexibility, with high-quality data delivered to ensure clients’ success. We offer two types of models for each cancer: the basic model and the immuno-oncology model.
3D BIOPRINTED MODELS
Carcinotech offers 3D bioprinted models of cancer microenvironments developed from established cells lines, patient-specific cells (including cancer stem cells) and biopsy samples.
Reduction in animal testing, defined animal-free conditions, up to 40% reduction in plastics, reagents usage
We develop models according to the client’s drug discovery and testing needs
Precision medicine testing
We get biopsy samples from a diverse population offering precision drug testing for effective treatments
30% cheaper than other 3D models
4x faster than current solutions
CarcinoGBM™ are the 3D bioprinted models of the glioblastoma microenvironment, offering a platform for in vitro high-throughput, accurate and rapid drug discovery and screening for novel, combinatorial, and repurposed drugs. Our models can be used for drug efficacy, drug pathway, and toxicity testing and are bioengineered to de-risk cancer drug discovery, offering translational data with respect to cancer heterogeneity and microenvironments. We offer 2 different types of CarcinoGBM models:
CarcinoTNBC™ and CarcinoER™
These are 3D bioprinted models of the triple negative breast cancer (CarcinoTNBC™) and estrogen receptor positive (CarcinoER™) microenvironments offering a platform for in vitro high throughput drug screening. The basic model consists of 4 different cell types and immuno-oncology models have additional tumour infiltrating lymphocytes and tumour associated macrophages. We can develop patient-specific models of different mutations, from different populations, offering a more global approach to drug testing.
These are 3D bioprinted models of the lung cancer microenvironment particularly non-small cell lung cancer. These assay ready models allow for rapid screening of multiple drugs, with accurate predictions of how the drug would work in clinical trials. The basic model with 4 different cell types and immuno-oncology model with 6 different cell types gives flexibility to suit your research needs. These models can also be used to test chemotherapy, radiation therapy and immunotherapy candidates.
We can also make bespoke models for these cancers and other solid tumours to suit your drug discovery and testing needs. We can include the cell types you would like in the models, which can simplify, accelerate, and provide a sustainable platform for drug discovery. Our models are physiologically relevant and are completely animal component-free, making them defined with no batch-to-batch variations.